Your fact-checks will appear here
Independent panel of experts in primary care and prevention
The available sources show that 2025 ACC/AHA guidance — as reflected in the 2025 Acute Coronary Syndromes (ACS) guideline and related summaries — keeps aggressive lipid management in high-risk and sec...
Major U.S. and specialty guidance in 2024–2025 centers statin decisions on adults roughly aged 40–75 years, using an estimated 10‑year ASCVD risk plus risk enhancers: many groups (USPSTF; ACC/AHA-deri...
Randomized trials and systematic reviews show multi‑ingredient (multivitamins or complex mixes) generally do not outperform single‑ingredient interventions in preventing cardiovascular events or impro...
The 2025 guidance landscape continues to direct high‑intensity statins for people with established atherosclerotic cardiovascular disease (ASCVD), those with LDL‑C ≥190 mg/dL, and many patients after ...
Cologuard is an FDA‑approved, at‑home multitarget stool DNA (MT‑sDNA) test intended to screen average‑risk adults 45 and older for colorectal cancer (colon and rectal cancer) and certain precancerous ...
Available reporting and guidelines say mammograms are X‑ray exams used to detect breast cancer early and that screening has been linked to large reductions in breast‑cancer deaths; the U.S. Preventive...
Dr. Sanjay Gupta’s commonly cited brain-health supplement ingredients — including ashwagandha, curcumin/turmeric, phosphatidylserine, choline, lion’s mane, and assorted polyphenols — show in small or ...
Making statins available over the counter (OTC) promises measurable reductions in heart attacks and strokes by expanding access to under-treated moderate‑risk adults, but it would also shift responsib...
Randomized‑trial evidence is clearest for a small set of single‑ingredient supplements: omega‑3 (n‑3) fatty acids show modest reductions in and coronary events, lowers stroke risk in some large trials...
Major U.S. guideline panels diverge on in men: the USPSTF finds evidence insufficient to recommend population-wide screening for men, while specialty societies (, and international groups) advise targ...
relies on structured history-taking, collateral informant reports, cognitive screening and more detailed neuropsychological and neurological testing, supplemented by laboratory tests and when indicate...
Clinicians should go beyond calcium and vitamin D alone and start pharmacologic osteoporosis therapy when a patient’s measured bone density, recent fracture history, or validated fracture-risk calcula...
Major cardiology and preventive medicine bodies now advise against routine initiation of low‑dose aspirin for primary prevention in older adults: the U.S. Preventive Services Task Force (USPSTF) recom...
Vitamin D supplements clearly change blood levels and help people with deficiency — they reduce cancer mortality by about 12–13% in meta-analyses and have shown benefits in randomized trials for telom...
Recent large reviews and trials show growing evidence that vitamin D affects more than bones: a 2025 MDPI review lists roles in immunity, pregnancy, brain function, cancer and cardiovascular health , ...
Evidence-based interventions for children exposed to grooming focus on prevention (education and brief online programs), training for adults and gatekeepers, and trauma-informed clinical care that add...
PSA levels alone do not reliably separate prostatitis from prostate cancer: PSA rises with cancer, benign prostatic hyperplasia (BPH), and inflammation, and can spike acutely with prostatitis then fal...
Federal lobbying and conflict-disclosure systems exist and are publicly searchable, but compliance gaps and differing rules across institutions mean finding disclosures tied to specific contractors or...
Recent long-term trials show PSA screening can reduce prostate cancer deaths by about 13% over 23 years (absolute risk reduction ~0.22%) but also causes substantial overdiagnosis and harms; expert bod...
Major 2024–2025 guidelines and reviews treat diabetes, chronic kidney disease (CKD), and familial hypercholesterolemia (FH) as “statin‑indicated” or risk‑enhancing conditions that lower the threshold ...